Minneapolis Veterans Affairs Healthcare System, Minneapolis, MN; Department of Medicine, University of Minnesota, Minneapolis, MN.
Minneapolis Veterans Affairs Healthcare System, Minneapolis, MN.
Am J Kidney Dis. 2015 Nov;66(5):823-36. doi: 10.1053/j.ajkd.2014.11.031.
In 2006, NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative) published clinical practice guidelines for hemodialysis adequacy. Recent studies evaluating hemodialysis adequacy as determined by initiation timing, frequency, duration, and membrane type and prompted an update to the guideline.
Systematic review and evidence synthesis.
SETTING & POPULATION: Patients with advanced chronic kidney disease receiving hemodialysis.
We screened publications from 2000 to March 2014, systematic reviews, and references and consulted the NKF-KDOQI Hemodialysis Adequacy Work Group members. We included randomized or controlled clinical trials in patients undergoing long-term hemodialysis if they reported outcomes of interest.
Early versus late dialysis therapy initiation; more frequent (>3 times a week) or longer duration (>4.5 hours) compared to conventional hemodialysis; low- versus high-flux dialyzer membranes.
All-cause and cardiovascular mortality, myocardial infarction, stroke, hospitalizations, quality of life, depression or cognitive function scores, blood pressure, number of antihypertensive medications, left ventricular mass, interdialytic weight gain, and harms or complications related to vascular access or the process of dialysis.
We included 32 articles reporting on 19 trials. Moderate-quality evidence indicated that earlier dialysis therapy initiation (at estimated creatinine clearance [eClcr] of 10-14mL/min) did not reduce mortality compared to later initiation (eClcr of 5-7mL/min). More than thrice-weekly hemodialysis and extended-length hemodialysis during a short follow-up did not improve clinical outcomes compared to conventional hemodialysis and resulted in a greater number of vascular access procedures (very low-quality evidence). Hemodialysis using high-flux membranes did not reduce all-cause mortality, but reduced cardiovascular mortality compared to hemodialysis using low-flux membranes (moderate-quality evidence).
Few studies were adequately powered to evaluate mortality. Heterogeneity of study designs and interventions precluded pooling data for most outcomes.
Limited data indicate that earlier dialysis therapy initiation and more frequent and longer hemodialysis did not improve clinical outcomes compared to conventional hemodialysis.
2006 年,NKF-KDOQI(美国肾脏基金会-肾脏病预后质量倡议)发布了血液透析充分性的临床实践指南。最近的研究评估了血液透析充分性,包括起始时间、频率、时长和膜类型,这促使指南进行了更新。
系统评价和证据综合。
接受血液透析的晚期慢性肾脏病患者。
我们筛选了 2000 年至 2014 年 3 月的出版物、系统评价和参考文献,并咨询了 NKF-KDOQI 血液透析充分性工作组的成员。如果报告了感兴趣的结局,我们纳入了长期血液透析患者的随机或对照临床试验。
早期与晚期透析治疗开始;与常规血液透析相比,更频繁(每周>3 次)或更长时间(>4.5 小时);低通量与高通量透析器膜。
全因和心血管死亡率、心肌梗死、卒、住院、生活质量、抑郁或认知功能评分、血压、降压药物数量、左心室质量、透析间体重增加,以及与血管通路或透析过程相关的危害或并发症。
我们纳入了 32 篇报告 19 项试验的文章。中等质量证据表明,与晚期开始(估计肌酐清除率[eClcr]为 5-7mL/min)相比,早期开始(eClcr 为 10-14mL/min)的透析治疗并不能降低死亡率。与常规血液透析相比,短时间内每周三次以上的血液透析和延长的血液透析并不能改善临床结局,反而会增加更多的血管通路程序(极低质量证据)。与低通量膜相比,高通量膜血液透析并未降低全因死亡率,但降低了心血管死亡率(中等质量证据)。
很少有研究有足够的能力评估死亡率。研究设计和干预措施的异质性使得大多数结局的数据无法进行汇总。
有限的数据表明,与常规血液透析相比,早期透析治疗开始、更频繁和更长时间的血液透析并没有改善临床结局。